CeriBell (NASDAQ:CBLL) CRO Sells $24,804.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,378 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $24,804.00. Following the completion of the transaction, the executive directly owned 56,291 shares of the company’s stock, valued at $1,013,238. This trade represents a 2.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Performance

NASDAQ:CBLL opened at $18.67 on Friday. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $708.34 million, a PE ratio of -11.45 and a beta of 0.99. The firm has a 50-day moving average price of $19.07 and a 200 day moving average price of $19.34.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. Research analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on CBLL shares. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Canaccord Genuity Group dropped their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $22.20.

Institutional Trading of CeriBell

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of CeriBell by 11.1% during the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares in the last quarter. KCM Capital Inc increased its holdings in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares in the last quarter. Yu Fan increased its holdings in shares of CeriBell by 10.7% in the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after purchasing an additional 1,162,200 shares in the last quarter. Finally, Novo Holdings A S increased its holdings in shares of CeriBell by 2.3% in the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock valued at $16,857,000 after purchasing an additional 20,000 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.